Receptos Announces Pricing of Initial Public Offering of Common Stock

SAN DIEGO, May 8, 2013 (GLOBE NEWSWIRE) -- Receptos, Inc.
(Nasdaq:RCPT), a biopharmaceutical company developing therapeutic
candidates for the treatment of immune and metabolic diseases, today
announced the pricing of its initial public offering of 5,200,000
shares of its common stock at an initial public offering price of
$14.00 per share. The shares of Receptos' common stock are expected to
begin trading on the Nasdaq Global Market under the symbol "RCPT" on
May 9, 2013. All of the shares of common stock are being offered by
Receptos. In addition, Receptos has granted the underwriters a 30-day
option to purchase up to an additional 780,000 shares of common stock
to cover over-allotments, if any. The offering is expected to close on
May 14, 2013, subject to customary closing conditions.

Credit Suisse Securities (USA) LLC, Leerink Swann LLC and BMO Capital
Markets are acting as joint book-running managers for the offering.
Wedbush PacGrow Life Sciences is acting as a co-manager.

A registration statement relating to these securities was declared
effective by the Securities and Exchange Commission on May 8, 2013. The
offering is being made only by means of a prospectus. Copies of the
prospectus relating to the offering may be obtained from Credit Suisse
Securities (USA) LLC, Attention: Prospectus Department, One Madison
Avenue, New York, NY 10010, Telephone: (800) 221-1037, Email:
[email protected]suisse.com; from Leerink Swann LLC,
Attention: Syndicate Department, One Federal Street, 37th Floor,
Boston, MA 02110, Telephone: (800) 808-7525, Email:
[email protected]; or from BMO Capital Markets, Attention: Equity
Syndicate Department, 3 Times Square, New York, NY 10036, Telephone:
(800) 414-3627, Email: [email protected].

This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of these
securities in any state or other jurisdiction in which such an offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or other
jurisdiction.

About Receptos

Receptos is a biopharmaceutical company developing therapeutic
candidates for the treatment of immune and metabolic diseases. The
company's lead program, RPC1063, is a sphingosine 1-phosphate 1
receptor (S1P1R) small molecule modulator candidate for immune
indications, including relapsing multiple sclerosis (RMS) and
inflammatory bowel disease (IBD). The company is also developing
RPC4046, an anti-interleukin-13 (IL-13) antibody for an
allergic/immune-mediated orphan disease, eosinophilic esophagitis
(EoE). Receptos has established expertise in high resolution protein
crystal structure determination, biology and drug discovery for
G-protein-coupled receptors (GPCRs).


CONTACT: Media and Investor Contact:
         Graham K. Cooper
         Chief Financial Officer, Receptos
         (858) 652-5708
         [email protected]

Suggested Articles

Journey Colab launches with $3 million from Apollo Projects to develop a pipeline of psychedelic compounds through a new development model.

Forma's lead asset, an IDH1 inhibitor, cleared cancer in one-third of patients with relapsed or refractory acute myeloid leukemia.

A type of white blood cell known as a granulocyte secretes growth factors that help axons of the central nervous system regenerate, researchers found.